/
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Malignant Glioma is an emerging landscape with 18 programs across 31 companies. The most active players are Laminar Pharmaceuticals.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Bubble size = clinical trials
Key Players
Pipeline
Analysis
93%
Small molecule
13 of 14 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.
Analysis
199
clinical trials
Clinical Trials
199 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)